Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nab-paclitaxel, Carboplatin, AC + Bevacizumab in TNBC
NCT00777673Phase 2Unknown
- Sponsor
- University of Tennessee Cancer Institute
- Start
- Oct 2008
- Primary completion
- Jan 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in triple-negative breast cancer (TNBC), sponsored by University of Tennessee Cancer Institute. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00777673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777673.